Agilent Acquired Proscia for $240 Million

The acquisition expands Agilent's footprint in the AI-enabled digital pathology market.

Updated on Oct. 13, 2026 in Healthcare

Agilent Acquired Proscia for $240 Million

Live Poll

Do you trust that corporate acquisitions of AI software companies will ultimately benefit the public?

Agilent Technologies has agreed to acquire Proscia for $240 million in cash to bolster its digital pathology capabilities. The deal, which includes an additional $30 million in potential performance-based payments, is expected to close in early fiscal 2027.

Why it matters

The acquisition positions Agilent to integrate AI-driven analysis directly into its existing pathology diagnostic workflows. By securing this software, the company aims to scale its presence in the rapidly growing field of automated laboratory imaging.

Agilent is paying $240 million in cash for Proscia, which recorded over $18 million in revenue during the past 12 months. The deal also includes up to $30 million in performance-based payments that may be triggered post-closing.

The players

Agilent Technologies

A global leader in life sciences, diagnostics, and applied chemical markets providing laboratory instruments and software.

Proscia

A developer of digital pathology software platforms that utilize AI to assist in clinical and research analysis of tissue slides.

The details

Proscia provides software that digitizes physical pathology slides to enable AI-powered diagnostic analysis. The integration follows a multi-year distribution agreement established by the two firms in 2022. By bringing this technology in-house, Agilent intends to streamline the diagnostic pathway for laboratories currently relying on disparate digital imaging tools.

2022: Companies entered a multi-year distribution agreement.
October 13, 2026: Agilent announced the acquisition of Proscia.
Early fiscal 2027: The acquisition is expected to close.

Market Landscape

This acquisition represents the full integration of a commercial partnership that began with a 2022 distribution agreement between the two firms. It reflects a broader industry trend where diagnostic equipment providers acquire specialized AI software developers to secure proprietary digital pathology pipelines.

Operators in the diagnostic space should monitor how Agilent integrates these AI tools into existing laboratory hardware suites to gauge potential changes in procurement requirements. The shift signals a tightening competitive landscape for proprietary software-hardware diagnostic bundles.

The takeaway

The move underscores the growing premium placed on AI-driven diagnostic software that integrates with existing hardware infrastructure. Owners should evaluate whether their current diagnostic vendors have a roadmap for similar digital pathology capabilities to avoid potential compatibility gaps.